Phenominer Database Results (10 results)

 

Table "column sort" updates the order of the bars in the chart.
Strain Phenotype Conditions Study Experiment Name Sex Age # of Animals Value Units SEM SD Method Method Duration Post Insult Time Value Clinical Measurement Notes Record ID Study ID
SHRSP/A3N ratio of deaths related to left ventricular hypertrophy to total study population during a period of time control condition Willette RN, etal., J Cardiovasc Pharmacol. 2001 Oct;38(4):606-17. doi: 10.1097/00005344-200110000-00013. total life span male 182 days-210 days 20 0.0 % unspecified method 0.0 0 ratio of deaths related to left ventricular hypertrophy to total study population during a period of time (CMO:0003810) 107933 3100
SHRSP/A3N ratio of deaths related to left ventricular hypertrophy to total study population during a period of time standard condition (for 126 days) Barone FC, etal., Pharmacology. 2007;80(2-3):166-76. doi: 10.1159/000103384. Epub 2007 Jun 4. total life span male 203 days-224 days 20 0.0 % unspecified method 0.0 0 ratio of deaths related to left ventricular hypertrophy to total study population during a period of time (CMO:0003810) 107114 3075
SHRSP/A3N ratio of deaths related to chronic hypertension to total study population during a period of time controlled sodium chloride content drinking water (1 %) (for 84 days) and controlled fat content diet (24.5 %) (for 84 days) and eprosartan (60 mg/kg/d) (for 84 days) Abrahamsen CT, etal., J Pharmacol Exp Ther. 2002 Apr;301(1):21-8. doi: 10.1124/jpet.301.1.21. total life span male 168 days-189 days 25 0.0 % unspecified method 0.0 0 ratio of deaths related to chronic hypertension to total study population during a period of time (CMO:0003800) 107519 3090
SHRSP/A3N ratio of deaths related to left ventricular hypertrophy to total study population during a period of time controlled sodium chloride content drinking water (1 %) (for 112 days) and controlled fat content diet (24.5 %) (for 112 days) and controlled enrasentan content diet (2400 ppm) (for 112 days) Willette RN, etal., J Cardiovasc Pharmacol. 2001 Oct;38(4):606-17. doi: 10.1097/00005344-200110000-00013. total life span male 182 days-210 days 20 10.0 % unspecified method 0.0 0 ratio of deaths related to left ventricular hypertrophy to total study population during a period of time (CMO:0003810) 107936 3100
SHRSP/A3N ratio of deaths related to left ventricular hypertrophy to total study population during a period of time controlled sodium chloride content drinking water (1 %) (for 126 days) and controlled fat content diet (24.5 %) (for 126 days) Barone FC, etal., Pharmacology. 2007;80(2-3):166-76. doi: 10.1159/000103384. Epub 2007 Jun 4. total life span male 203 days-224 days 20 55.0 % unspecified method 0.0 0 ratio of deaths related to left ventricular hypertrophy to total study population during a period of time (CMO:0003810) 107113 3075
SHRSP/A3N ratio of deaths related to chronic hypertension to total study population during a period of time control condition Abrahamsen CT, etal., J Pharmacol Exp Ther. 2002 Apr;301(1):21-8. doi: 10.1124/jpet.301.1.21. total life span male 168 days-189 days 25 0.0 % unspecified method 0.0 0 ratio of deaths related to chronic hypertension to total study population during a period of time (CMO:0003800) 107517 3090
SHRSP/A3N ratio of deaths related to left ventricular hypertrophy to total study population during a period of time controlled sodium chloride content drinking water (1 %) (for 126 days) and controlled fat content diet (24.5 %) (for 126 days) and controlled carvedilol content diet (2400 ppm) (for 126 days) Barone FC, etal., Pharmacology. 2007;80(2-3):166-76. doi: 10.1159/000103384. Epub 2007 Jun 4. total life span male 203 days-224 days 20 0.0 % unspecified method 0.0 0 ratio of deaths related to left ventricular hypertrophy to total study population during a period of time (CMO:0003810) 107112 3075
SHRSP/A3N ratio of deaths related to left ventricular hypertrophy to total study population during a period of time controlled sodium chloride content drinking water (1 %) (for 112 days) and controlled fat content diet (24.5 %) (for 112 days) and controlled enrasentan content diet (1200 ppm) (for 112 days) Willette RN, etal., J Cardiovasc Pharmacol. 2001 Oct;38(4):606-17. doi: 10.1097/00005344-200110000-00013. total life span male 182 days-210 days 20 5.0 % unspecified method 0.0 0 ratio of deaths related to left ventricular hypertrophy to total study population during a period of time (CMO:0003810) 107935 3100
SHRSP/A3N ratio of deaths related to chronic hypertension to total study population during a period of time controlled sodium chloride content drinking water (1 %) (for 63 days) and controlled fat content diet (24.5 %) (for 63 days) and vehicle control condition (for 63 days) Abrahamsen CT, etal., J Pharmacol Exp Ther. 2002 Apr;301(1):21-8. doi: 10.1124/jpet.301.1.21. total life span male 147 days-168 days 25 95.0 % unspecified method 0.0 0 ratio of deaths related to chronic hypertension to total study population during a period of time (CMO:0003800) 107518 3090
SHRSP/A3N ratio of deaths related to left ventricular hypertrophy to total study population during a period of time controlled sodium chloride content drinking water (1 %) (for 112 days) and controlled fat content diet (24.5 %) (for 112 days) Willette RN, etal., J Cardiovasc Pharmacol. 2001 Oct;38(4):606-17. doi: 10.1097/00005344-200110000-00013. total life span male 182 days-210 days 20 65.0 % unspecified method 0.0 0 ratio of deaths related to left ventricular hypertrophy to total study population during a period of time (CMO:0003810) 107934 3100